Last reviewed · How we verify

RBP-6000 — Competitive Intelligence Brief

RBP-6000 (RBP-6000) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor partial agonist (long-acting depot). Area: Psychiatry / Substance Use Disorder.

phase 3 Opioid receptor partial agonist (long-acting depot) Mu-opioid receptor (μ-OR) Psychiatry / Substance Use Disorder Small molecule Live · refreshed every 30 min

Target snapshot

RBP-6000 (RBP-6000) — Indivior Inc.. RBP-6000 is a subcutaneous depot formulation of buprenorphine that provides sustained opioid receptor partial agonism for extended periods.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RBP-6000 TARGET RBP-6000 Indivior Inc. phase 3 Opioid receptor partial agonist (long-acting depot) Mu-opioid receptor (μ-OR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor partial agonist (long-acting depot) class)

  1. Indivior Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBP-6000 — Competitive Intelligence Brief. https://druglandscape.com/ci/rbp-6000. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: